This cohort included seven female and three male who were diagnosed as WHO grade III or IV glioma, Specifically, six IDH wild-type glioblastoma (GBM) (60%), three IDH mutant low-grade (III) glioma and 1 IDH mutant GBM (40%) according to the 2016 WHO brain tumor classification with IDH status (15). This evidence concerns the gene IDH1 and glioma.